Navigation Links
Hospira Names John B. Elliot Senior Vice President of Operations
Date:4/11/2012

LAKE FOREST, Ill., April 11, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, today announced that John B. Elliot has been named senior vice president, Operations, effective April 16. In this role, Mr. Elliot will have overall responsibility for Hospira's global operations organization and serve as a member of Hospira's senior leadership team. He will report directly to F. Michael Ball, chief executive officer.

"John is a seasoned global leader with more than 35 years of broad manufacturing experience across production, logistics and supply, and specific expertise in injectable pharmaceuticals," said Mr. Ball. "With his proven track record in driving improvements in quality, service and operational effectiveness, we're confident John will have an immediate, positive impact as we continue our efforts to deliver high-quality, cost-effective products to customers and ultimately establish our manufacturing operations as a strategic, competitive advantage."

Mr. Elliot, 60, has most recently advised some of the world's largest pharmaceutical companies in his role as an operations consultant. He previously served as president and chairman at Cherokee Pharmaceuticals, LLC (subsequently acquired by Merck & Co.), a U.S.-based active ingredients manufacturing company, where he led the organization from start-up to become a significant competitor in the contract manufacturing marketplace. Prior to Cherokee, Mr. Elliot spent 26 years with GlaxoSmithKline plc (formerly SmithKline Beecham), most recently serving as senior vice president. During his tenure, he held various roles of progressive responsibility in the operations organization and was credited for inculcating a high-performance culture across his plant network.

Under Mr. Elliot's leadership, Hospira will advance its plant remediation strategies and create additional manufacturing capacity, including the construction of a new 1.1 million square-foot, state-of-the-art facility in India. Mr. Elliot joins an operations leadership team that has recently been strengthened by the addition of top industry talent, including the appointment of Zena G. Kaufman as Hospira's new senior vice president of Quality in February.

Born and educated in Scotland, Mr. Elliot earned his bachelor's degree, with honors, in chemical engineering from Heriot-Watt University in Edinburgh.

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Hospira Names Zena G. Kaufman Senior Vice President of Quality; Strengthens Quality and Compliance Capabilities With Addition of Top Industry Talent
2. Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement
3. Hospira Receives Favorable Court Decision on Eloxatin(R)
4. Hospira Announces Plans to Integrate Symbiq(R) and EndoTool(R) Technologies
5. Hospira Names Brian Meadows Supply Chain Chief
6. Hospira Supports Newly Introduced Biogenerics Legislation
7. Hospira Advances Patient Safety With New GemStar(R) SP Infusion System
8. StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists
9. Hospira Hosts Conference Call for Third-Quarter 2008 Earnings
10. Human Genome Sciences Announces Process Development and Manufacturing Alliance With Hospira
11. Health Diagnostic Laboratory Names Scott Blackwell Vice President of Corporate Culture
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... There is no saying when ... relentless pressures in pricing and lack in consumer confidence. ... though - numerous opportunities are up for grabs but ... presents four names in this sector: Portola Pharmaceuticals Inc. ... VTAE ), Anthera Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/18/2016)... ... 2016 , ... Shimadzu Scientific Instruments announces its sponsorship of ... two-day camp will take place annually starting June 2016. It will provide qualifying ... preparation for a university academic program. , The laboratory- and technology-focused camp ...
(Date:5/18/2016)... Kansas (PRWEB) , ... May 18, 2016 , ... Ryan ... given a life expectancy in the late teens to early twenties. DMD is a ... In 2009, at the age of 22, Benton’s condition was critical. He met with ...
(Date:5/17/2016)... New York, NY (PRWEB) , ... May 17, 2016 , ... ... Awareness Month, buildings, bridges, and monuments across the globe will show their support in ... of NF. , Neurofibromatosis, NF, is a genetic disorder that causes tumors to ...
Breaking Biology Technology:
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/14/2016)... 2016 http://www.apimages.com ) - ... - Renvoi : image disponible via AP Images ... --> DERMALOG, le leader de ... lecteurs d,empreintes digitales pour l,enregistrement des réfugiés en ... pour produire des cartes d,identité aux réfugiés. DERMALOG ...
Breaking Biology News(10 mins):